Literature screening is often mistaken for reading. In practice, it is a repeatable intake process: define the question, search, remove duplicates, screen records, capture reasons, and route items for expert review.
Workload model
Peptide teams should report records received, duplicates removed, abstracts screened, full texts requested, and items escalated. PubMed and ClinicalTrials.gov are discovery sources, not a substitute for an internal evidence register. A useful planning estimate is 5 to 10 minutes for a straightforward title or abstract screen and materially longer for full-text extraction. Treat those as queue assumptions, not published clinical benchmarks.
| Stage | Required field | Quality control |
|---|---|---|
| Search | query, date, database | save the exact query |
| Triage | include, exclude, unclear | require a reason code |
| Extraction | endpoint, population, source | second-person review for key claims |
| Handoff | question for scientist | no unsupported interpretation |
Evidence and boundaries
NCBI reference material helps staff understand terminology, while FDA pages anchor safety and product-status boundaries. A coordinator may normalize citations, maintain a deduplication sheet, and prepare a weekly digest. They should not make a clinical conclusion, change inclusion criteria without approval, or present an investigational finding as established care.
Use a versioned protocol. Record who approved the question, the date of the search, and any changes. If a record involves patient or trial data, apply the team's privacy and access controls. The BLS role description is a useful reminder that administrative support is valuable when it is clearly separated from professional judgment.
Methodology & Sources
The evidence log includes PubMed peptide results, ClinicalTrials.gov peptide records, NCBI Bookshelf, FDA compounding information, FDA safety communications, HHS privacy guidance, CMS administrative simplification, BLS medical-assistant duties, AHRQ primary-care resources, ASA standards, NABP accreditation resources, and AMA prior-authorization guidance. These sources support the workflow and governance recommendations; workload figures are explicitly planning estimates.
FAQ
Can a coordinator screen abstracts?
Yes, against an approved protocol, with unclear records routed to a subject-matter reviewer.
What is the most useful metric?
Screening throughput paired with agreement or rework rate, not raw record count alone.
How often should searches run?
Set a cadence based on the decision being supported and record each run.
PeptideStaff implication: a research assistant can maintain the evidence register so scientists spend more time on interpretation.
Sources & Citations
- https://pubmed.ncbi.nlm.nih.gov/?term=peptide+drug+development
- https://clinicaltrials.gov/search?term=peptide
- https://www.ncbi.nlm.nih.gov/books/NBK470578/
- https://www.fda.gov/drugs/drug-supply-chain-integrity/compounding-and-drug-products
- https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/drug-safety-communications
- https://www.hhs.gov/hipaa/for-professionals/privacy/index.html
- https://www.cms.gov/medicare/regulations-guidance/administrative-simplification/hipaa
- https://www.bls.gov/ooh/healthcare/medical-assistants.htm
- https://www.ahrq.gov/topics/primary-care.html
- https://www.asahq.org/standards-and-guidelines
- https://www.nabp.pharmacy/programs/accreditation/
- https://www.ama-assn.org/practice-management/prior-authorization
Topics
PeptideStaff Research Team
Peptide Industry Research & Analytics
Market research analysts | peptide industry data specialists | healthcare economists
Our research team aggregates and analyzes publicly available data from regulatory agencies, market research firms, and clinical databases to deliver statistics-backed insights for peptide business owners. All statistics are sourced and cited.
Published by the PeptideStaff Research Team, July 2026